Et stort sammenlignings mortalitetsstudie (INJECT) med ca 6000 patienter viste at reteplase reducerer risikoen for hjertesvigt (sekundær effekt kriterie) signifikant og mindst lige så stor reduktion af mortalitet (primær effekt kriterie), sammenlignet med streptokinase.
6000 patients showed that reteplase reduced the incidence of heart failure (secondary efficacy criterion) in a significant manner and was at least equally effective in terms of reducing mortality (primary efficacy criterion) when compared to streptokinase.